Objective To investigate the correlations between serum neuropeptide Y (NPY) levels and disease severity in patients with cervical vertigo and the efficacy of the blade needle.Methods Eighty-eight cervical vertigo patients diagnosed in our hospital were enrolled, while another 86 healthy people were selected as controls. Serum NPY and serum calcitonin gene-related peptide (CGRP) levels were measured by enzyme-linked immunosorbent assay (ELISA). The severity of vertigo was graded by visual analog scores. Cranial Doppler ultrasound (TCD) was used to measure the mean blood flow and mean blood flow velocity of the base artery as well as the left and right vertebral arteries. Finally, the changes of indicators before and after the blade needle treatment were compared.Results Serum NPY levels were significantly higher in patients with cervical vertigo than in healthy controls[(509.7±80.8) pg/ml vs (433.8±66.1) pg/ml, P<0.001], and in the severe group than in the moderate and mild groups. In addition, these levels were markedly elevated in the moderate group than in the mild group. There was a strong positive correlation between the serum NPY level and the visual analog score(r=0.421,P<0.001). However, serum NPY levels were negatively correlated with mean blood flow(r=-0.361,P<0.001) and mean blood flow velocity(r=-0.472,P<0.001) and serum CGRP levels(r=-0.380,P<0.001). All indicators were improved after blade needle treatment (P<0.05).Conclusions Serum NPY levels are positively correlated with disease severity in cervical vertigo patients. The mechanism may be associated with down-regulation of NPY.
Key words
neuropeptide Y /
cervical vertigo /
disease severity /
blade needle
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] West N, Hansen S, Moller M N, et al. Repositioning chairs in benign paroxysmal positional vertigo: implications and clinical outcome[J]. Eur Arch Otorhinolaryngol,2016,273(3): 573-580.
[2] Li, Y, Peng, B. Pathogenesis, diagnosis, and treatment of cervical vertigo[J]. Pain Physician,2015, 18(4): E583-E595.
[3] Habler H J, Stegmann J U, Timmermann L, et al. Functional evidence for the differential control of superficial and deep blood vessels by sympathetic vasoconstrictor and primary afferent vasodilator fibres in rat hairless skin[J]. Exp Brain Res,1998,118(2):230-234.
[4] Chronwall B M, Zukowska Z. Neuropeptide Y, ubiquitous and elusive[J]. Peptides, 2004,25(3):359-63.
[5] Pheng L H, Regoli D. Receptors for NPY in peripheral tissues bioassays[J].Life Sci,2000,67(8):847-62.
[6] Jacques D, Abdel-Samad D. Neuropeptide Y (NPY) and NPY receptors in the cardiovascular system: implication in the regulation of intracellular calcium[J].Can J Physiol Pharmacol, 2007,85(1):43-53.
[7] Kuo L E, Abe K, Zukowska Z. Stress, NPY and vascular remodeling: implications for stress-related diseases[J].Peptides, 2007,28(2):435-440.
[8] 姜布平,赵爱英.毫针、刃针联合治疗颈性眩晕800例[J].辽宁中医杂志,2013,40(11):2347-2348
[9] 王慧敏,曾浩彬,陈文治,等.刃针松解术治疗颈性眩晕[J].广东医学,2012,33(3):366-368.
[10] 国家中医药管理局.中医病证诊断疗效标准[S].南京:南京大学出版社,1994:184-189.
[11] Zukowska Z, Pons J, Lee E W, et al. Neuropeptide Y: a new mediator linking sympathetic nerves, blood vessels and immune system?[J]. Can J Physiol Pharmacol, 2003, 81(2): 89-94.
[12] Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Rose W, et al. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium[J]. Circ Res, 1998(2),83: 187-195.
[13] Kitlinska J, Lee E W, Movafagh S, et al. Neuropeptide Y-induced angiogenesis in aging[J]. Peptides, 2002,23(1): 71-77.
[14] Sheng Y, Zhu L. The crosstalk between autonomic nervous system and blood vessels[J].Int J Physiol Pathophysiol Pharmacol, 2018,10(1):17-28.
PDF(657 KB)
